| Expression pattern: |
UP |
| Associated gene: |
EYA3, c-Myc, Ago2 |
| Associated microRNA: |
miR-223, miR-646 |
| Biological function: |
Promotes malignant progression of prostate cancer by enhancing proliferation, colony formation, migration, invasion, and tumor growth in vivo. |
| Molecular mechanism: |
Acts as a ceRNA to sponge miR-223, thereby increasing EYA3 expression and enhancing c-Myc expression/stability; involves Ago2-containing RISC interaction. |
| Biological pathway or process: |
proliferation (promotes); migration (promotes); invasion (promotes); cell cycle (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; divergent primers PCR; FISH / smFISH; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Transwell Assay; Wound Healing Assay; Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model |
| Clinical significance: |
Potential new targets for the diagnosis or treatment of prostate cancer. |
| Description: |
circGNG4 is upregulated in prostate cancer and functions as an oncogenic circRNA. It mainly localizes to the cytoplasm and sponges miR-223, thereby increasing EYA3 and promoting c-Myc expression/stability to drive cell-cycle progression and malignant phenotypes (proliferation, migration/invasion, and xenograft growth). |
| Confidence score: |
0.8365 |